FOXO4-DRI describes a D-retro-inverso peptide design intended to mimic the side-chain topology of a FOXO4 interaction segment while reversing backbone direction. It is not equivalent to an ordinary all-L peptide with the same letter order.
Evidence at a glance
- “DRI” denotes D-retro-inverso construction; D stereochemistry and reversed residue order are identity-critical.
- Cell penetration, sequence, terminal form and counterion should be documented for the exact construct.
- A senolytic cell assay is not a substitute for chemical identity, purity or in-vivo safety.
Identity record
Retro-inverso design reverses peptide-bond direction while using D amino acids. A one-letter sequence copied without orientation and stereochemistry can describe the wrong molecule.
Analytical and evidence boundary
Chemical identity and functional activity require separate evidence. A cell assay may be affected by cell state, uptake and assay conditions, while LC-MS identity says nothing by itself about senolytic selectivity.
Product copy should use “investigated in senescent-cell and mouse aging models.” It should not use “reverses aging,” “rejuvenates humans” or disease-treatment language.
Editorial rule
State the exact material, form, model or population and endpoint supported by the cited record. Do not convert mechanistic plausibility, an animal result, an official finished-drug label or an analytical test into a claim about an unrelated catalog lot.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Targeted apoptosis of senescent cells restores tissue homeostasisBaar MP, et al. Cell. 2017. PMID 28340339.
- FOXO4-DRI and age-related Leydig-cell dysfunctionPreclinical study. 2020. PMID 31959736.
- FOXO4-DRI and endothelial-cell senescence2026 endothelial and mouse-aging-model study; PMID 41625068.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
